Financial Performance - The total market value of the group's investment properties as of December 31, 2025, is approximately HKD 330.9 million, a decrease of about HKD 273.2 million compared to 2024[7]. - Rental income for the year ended December 31, 2025, is approximately HKD 21.2 million, a decrease of about 21.0% compared to 2024, primarily due to increased rental concessions[8]. - The net loss for the year ended December 31, 2025, is approximately HKD 267.7 million, compared to a net loss of HKD 234.3 million in 2024[11]. - The company's revenue for the fiscal year 2025 was HKD 21.2 million, a decrease from HKD 26.8 million in 2024[19]. - The total comprehensive expenses attributable to equity holders for 2025 amounted to approximately HKD 300.8 million, up from HKD 274.3 million in 2024[30]. - The basic loss per share for 2025 was approximately HKD 0.6932, an increase from HKD 0.6066 in 2024, representing a loss increase of about HKD 0.0866[30]. Investment Properties - The fair value of the group's investment properties decreased by approximately HKD 273.2 million in 2025, reflecting a decline in the overall market conditions for commercial retail and residential investment properties in Hong Kong[11]. - The fair value of the investment in the fund as of December 31, 2025, is approximately HKD 27.4 million, down from HKD 55.7 million as of December 31, 2024[9]. - The net change in fair value of investment properties decreased by HKD 273.2 million in 2025, compared to a decrease of HKD 247.3 million in 2024[19]. - The total rental income from personal investments as of December 31, 2025, was approximately HKD 2.7 million, with a total fair value of HKD 44.6 million[153]. Financial Position - As of December 31, 2025, the total equity was approximately HKD 307.3 million, down from HKD 608.0 million in 2024, a decrease of about HKD 300.7 million[32]. - The net current liabilities as of December 31, 2025, were approximately HKD 57.1 million, compared to HKD 7.6 million in 2024[31]. - The current ratio was approximately 0.16 as of December 31, 2025, down from about 0.91 in 2024[31]. - The total liabilities to equity ratio decreased to approximately 19.5% as of December 31, 2025, down from 21.7% as of December 31, 2024, primarily due to the repayment of all bank loans[36]. Capital Expenditures and Financing - The group recorded additional capital injection of approximately HKD 4.9 million into the Epic Capital Development Fund I, L.P. in 2025[9]. - Capital expenditures for the year ending December 31, 2025, were approximately HKD 4.9 million, down from HKD 6.2 million in 2024[37]. - The group plans to finance future capital expenditures primarily through cash generated from operations and bank borrowings, with potential consideration for raising additional funds at an appropriate time[37]. - The group fully repaid all bank loans by December 31, 2025, with a total repayment of approximately HKD 134.4 million in bank loans and interest, resulting in a bank loan balance of zero[34]. Corporate Governance - The company emphasizes effective corporate governance as a key factor for sustainable development and shareholder value[57]. - The board consists of seven members, including four executive directors and three independent non-executive directors[58]. - The company has adopted the corporate governance code as per the Stock Exchange Listing Rules[57]. - The board is responsible for managing all significant matters, including policy formulation and risk management systems[58]. - The company aims to ensure compliance with all applicable corporate governance code provisions for the fiscal year ending December 31, 2025[57]. Diversity and Employee Management - The board has adopted a diversity policy aiming for a long-term target of 30% female representation, currently achieving 57%[65]. - The gender distribution among employees shows 28.6% male and 71.4% female for the year 2025, maintaining a commitment to diversity[70]. - The company held four board meetings in the year ending December 31, 2025, with a full attendance rate from directors[73]. - Average training duration per employee was 4 hours, with all employees participating in environmental, social, and governance training courses[138]. Environmental, Social, and Governance (ESG) Initiatives - The company has established an Environmental, Social, and Governance (ESG) working group to oversee and evaluate the implementation of ESG initiatives[118]. - The company has complied with the ESG reporting guidelines and has not reported any significant non-compliance issues regarding environmental regulations[117]. - The company aims to optimize resource use to minimize environmental impact and promote environmental awareness among employees and tenants[120]. - The company has conducted a comprehensive materiality assessment in 2025 to prioritize various ESG issues affecting its business[124]. Compliance and Legal Matters - The company has a zero-tolerance policy towards bribery, extortion, fraud, and money laundering, ensuring compliance through a triple-check system for all financial matters[146]. - There were no significant legal cases related to corruption during the reporting period, indicating compliance with relevant laws and regulations[147]. - The company is currently addressing compliance issues related to building orders and warnings for several properties, with corrective works ongoing[159][160]. Shareholder Matters - The company proposed not to declare a final dividend for the years ending December 31, 2025, and December 31, 2024[168]. - The company has zero distributable reserves as of December 31, 2025, consistent with the previous year[179]. - Shareholders holding at least 10% of the paid-up capital can request the board to convene a special general meeting[111]. Audit and Risk Management - The audit committee, composed entirely of independent non-executive directors, is responsible for overseeing financial reporting and risk management systems[83]. - The Audit Committee held three meetings during the year ending December 31, 2025, to review the audited financial statements for the year ending December 31, 2024, and the unaudited interim financial statements for the six months ending June 30, 2025[85]. - The board is responsible for maintaining an effective internal control and risk management system, which is reviewed annually[106].

Financial Performance - The total revenue for the year ended December 31, 2025, was HKD 359,465,000, representing a 37.3% increase from HKD 261,781,000 in 2024[3] - The operating profit for 2025 was HKD 53,126,000, up from HKD 42,671,000 in 2024, indicating a growth of 24.5%[3] - The net profit attributable to the owners of the company for 2025 was HKD 20,932,000, a decrease of 22.5% from HKD 27,075,000 in 2024[3] - The company reported a pre-tax profit of HKD 28,657,000 for the year ended December 31, 2025, compared to HKD 36,990,000 in 2024, showing a decline of about 22.4%[13] - Total other income for 2025 was HKD 2,330,000, an increase of 51.5% from HKD 1,538,000 in 2024[23] - The company reported a significant increase in the provision for impairment losses, with HKD (4,612,000) in 2025 compared to HKD (3,743,000) in 2024[23] - For the fiscal year ending December 31, 2025, the company recorded revenue of HKD 359,465,000 and profit of HKD 20,932,000, compared to revenue of HKD 261,781,000 and profit of HKD 27,075,000 for the fiscal year ending December 31, 2024, indicating a revenue increase of approximately 37.3% but a profit decrease of about 22.8%[39] Assets and Liabilities - Total assets increased to HKD 1,738,826,000 in 2025, compared to HKD 1,400,616,000 in 2024, reflecting a growth of 24.1%[4] - The total liabilities rose to HKD 617,949,000 in 2025, up from HKD 307,662,000 in 2024, marking an increase of 101%[5] - Total liabilities increased to HKD 617,949,000 in 2025 from HKD 307,662,000 in 2024, representing a growth of about 101.5%[14] - The company's total liabilities increased to HKD 617,949,000 in 2025 from HKD 307,662,000 in 2024, resulting in a net debt of HKD 435,412,000[58] - The equity total rose to HKD 1,120,877,000 in 2025, compared to HKD 1,092,954,000 in 2024, leading to a debt-to-equity ratio of 39% in 2025, up from 17% in 2024[58] Earnings and Expenses - The company reported a basic and diluted earnings per share of HKD 0.78 for 2025, down from HKD 1.01 in 2024[3] - Employee benefits expenses increased to HKD 42,336,000 in 2025 from HKD 37,091,000 in 2024, representing a rise of 14.5%[3] - The company’s unallocated expenses for 2025 were HKD 14,509,000, compared to HKD 9,086,000 in 2024, indicating an increase of approximately 59.5%[13] - Total operating expenses for 2025 were HKD 49,595,000, up from HKD 46,921,000 in 2024, reflecting a rise of 5.7%[23] - Interest expenses from bank loans surged to HKD 17,209,000 in 2025, compared to HKD 1,403,000 in 2024, marking an increase of 1,126.5%[24] - Income tax expense for 2025 was HKD 7,725,000, a decrease of 22.1% from HKD 9,915,000 in 2024[26] Revenue Segments - The property development and investment segment generated revenue of HKD 1,466,000 for 2025, compared to HKD 1,511,000 in 2024, indicating a slight decrease of 3.0%[13] - Financial lending revenue increased significantly to HKD 350,777,000 in 2025 from HKD 257,469,000 in 2024, reflecting a growth of approximately 36.2%[13] - Interest income from financial lending operations was HKD 350,777,000 in 2025, compared to HKD 257,469,000 in 2024, indicating a growth of approximately 36.2%[18] - The number of active customers for unsecured loans increased from 15,523 as of December 31, 2024, to 19,935 as of December 31, 2025, contributing to revenue of approximately HKD 311,337,000, up from HKD 211,117,000 in the previous year[45] Investment and Market Strategy - The company will not explore investment opportunities in the property market in the short term due to the downturn in the Chinese property market[55] - The company has implemented strict loan application standards to minimize default risk and will actively assess its loan portfolio and risk control[55] - The company aims to evolve X Wallet into a comprehensive financial services platform, enhancing payment solutions and fund management[54] - The marketing strategy for the X Wallet includes a major brand promotion campaign aimed at distinguishing itself in the competitive fintech sector[54] - The company plans to launch ongoing product promotion activities for X Cash.AI starting January 2026, emphasizing its convenience and efficiency[55] Governance and Compliance - The company adhered to the corporate governance code and maintained high standards of corporate governance throughout the year ending December 31, 2025[61] - The audit committee reviewed the financial statements for the year ending December 31, 2025, ensuring accuracy and compliance with accounting principles[65] - The external auditor, PwC, confirmed that the financial statements align with the audited figures for the year ending December 31, 2025[66] - The board of directors includes both executive and independent non-executive members, ensuring a balanced governance structure[67] Customer and Loan Management - The company has a total of 57 mortgage loan customers as of December 31, 2025, with the top 10 customers accounting for 65% of the total receivables[46] - The company has established a system to identify and review overdue loan accounts, with a focus on the overall recovery capability of overdue assets[52] - The company wrote off receivables totaling approximately HKD 104,996,000 due to borrower bankruptcy and debtor death factors[49] - As of December 31, 2025, the net receivables of loans and interest amounted to HKD 1,135,735,000, with an expected credit loss provision of HKD 127,547,000[48] Cash and Financial Position - As of December 31, 2025, the company held approximately HKD 182.5 million in cash, representing about 31% of total current assets[57] - The company has no interim dividend for the six months ending June 30, 2025, and the board does not recommend a final dividend for the year ending December 31, 2025[40] - The company did not recommend any final dividend for the year ending December 31, 2025, consistent with 2024[27] - No shares of the company were purchased, sold, or redeemed by the company or its subsidiaries during the year[60]

Financial Performance - For the fiscal year ending December 31, 2025, the group's revenue was RMB 648.39 million, a decrease of 10.69% from RMB 725.96 million in the previous year[4]. - The net profit for the same period was RMB 66.06 million, down 25.51% from RMB 88.69 million year-on-year[4]. - Earnings attributable to the company's owners were RMB 39.63 million, a decline of 24.06% compared to RMB 52.18 million in the previous year[4]. - The basic and diluted earnings per share were RMB 0.31, compared to RMB 0.41 in the previous year[4]. - The total comprehensive income for the year was RMB 568.83 million, down from RMB 953.64 million in the previous year[13]. - The group reported a significant foreign currency translation loss of RMB 90.26 million, impacting overall comprehensive income[13]. - The company reported a profit attributable to owners of RMB 396,277,000 for 2025, a decrease of 24% from RMB 521,795,000 in 2024[53]. - The group’s profit before tax for 2025 is RMB 822,418,000, down from RMB 1,061,211,000 in 2024, indicating a decline of 22.5%[44]. - The annual profit for the same period was RMB 660,634,000, with a profit margin of approximately 8.95%[57]. - The annual profit for 2024 was RMB 886,933,000, indicating a profit margin of about 10.85%[59]. Revenue Breakdown - Traditional Chinese medicine product sales revenue in mainland China decreased to RMB 5,226,146 thousand in 2025 from RMB 5,897,495 thousand in 2024, representing a decline of approximately 11.4%[32]. - Total revenue from advertising services in mainland China was RMB 9,909 thousand in 2025, down from RMB 10,834 thousand in 2024, a decrease of about 8.5%[32]. - Total revenue for the year ending December 31, 2025, reached RMB 7,375,096,000, with external customer revenue contributing RMB 6,483,875,000[57]. Assets and Liabilities - Total assets decreased from RMB 14,408,591 thousand in 2024 to RMB 13,710,811 thousand in 2025, a decline of approximately 4.83%[15]. - Non-current assets decreased from RMB 3,575,115 thousand in 2024 to RMB 3,518,763 thousand in 2025, a decline of about 1.57%[15]. - Current assets decreased from RMB 10,833,476 thousand in 2024 to RMB 10,192,048 thousand in 2025, a decline of approximately 5.91%[15]. - Total liabilities decreased from RMB 4,243,512 thousand in 2024 to RMB 3,446,100 thousand in 2025, a decline of approximately 18.77%[16]. - Long-term borrowings increased from RMB 1,202,332 thousand in 2024 to RMB 1,453,334 thousand in 2025, an increase of about 20.92%[16]. - The net value of accounts receivable and notes was RMB 671,307,000 as of December 31, 2025, down from RMB 1,103,565,000 in 2024[64]. Cash Flow and Financial Ratios - The group achieved a significant increase in net cash flow from operating activities, indicating improved operational efficiency and cost control[7]. - Cash and cash equivalents increased from RMB 4,129,488 thousand in 2024 to RMB 4,704,271 thousand in 2025, an increase of approximately 13.87%[15]. - The current ratio as of December 31, 2025, was 5.72, indicating ample financial resources, compared to 3.81 in the previous year[100]. - The inventory turnover ratio was 1.34, reflecting a good inventory turnover speed compared to 1.47 in the previous year[100]. - The company’s capital debt ratio was 0.18 as of December 31, 2025, down from 0.22 in the previous year[101]. Expenses and Cost Management - The cost of raw materials, goods, and consumables consumed was RMB 2,723,149 thousand in 2025, down from RMB 2,963,249 thousand in 2024, indicating a reduction of about 8.1%[38]. - Research and development expenses amounted to RMB 82,759 thousand in 2025, slightly decreasing from RMB 84,823 thousand in 2024[38]. - The gross profit margin for the year ending December 31, 2025, was 38.03%, down from 39.64% in 2024, while the net profit margin was 10.19%, down from 12.22% in 2024, primarily due to rising raw material prices[103]. - For the year ending December 31, 2025, the group's sales expenses amounted to RMB 999.86 million, with a sales expense ratio of 0.15, a decrease from 0.18 in 2024[102]. Taxation - The income tax expense for the year 2025 is RMB 163,485,000, a decrease of 2.4% from RMB 168,480,000 in 2024[42]. - The effective tax rate for the group is 21.6% for 2025, compared to 21.2% in 2024[44]. - The income tax expense for mainland China is RMB 91,334,000 for 2025, an increase of 17.2% from RMB 77,891,000 in 2024[42]. - The deferred tax impact for 2025 includes a tax benefit of RMB 36,531,000 from tax incentives[44]. Strategic Focus and Future Outlook - The company emphasized a focus on quality and efficiency improvements, with ongoing reforms and management enhancements contributing to stable operations[6]. - The outlook for the traditional Chinese medicine industry is positive, supported by national strategies and increasing consumer demand for high-quality products[9]. - The group plans to strengthen its core competencies and transition from a scale-oriented approach to a quality and efficiency-driven model[9]. - The group aims to enhance product development and market expansion in the beauty and health sectors, focusing on high-quality development and resource allocation efficiency[118]. - The group will implement a work policy focusing on innovation, quality improvement, and management efficiency to enhance core competitive advantages and sustainable development capabilities in 2026[118]. Corporate Governance - The audit committee held five meetings in 2025 to review financial performance and risk management, ensuring compliance with internal controls and accounting policies[123]. - Ernst & Young has been appointed as the auditor for the fiscal year ending December 31, 2025, confirming the consistency of preliminary performance figures with the consolidated financial statements[127].

Financial Performance - The company reported a net profit of approximately RMB 11.1 million for the year ending December 31, 2025, compared to a net loss of approximately RMB 58.3 million for the year ending December 31, 2024[4]. - Adjusted EBITDA for the year was approximately RMB 360.9 million, an increase of about 27.3% from approximately RMB 283.4 million for the previous year[4]. - Total revenue for the year was approximately RMB 2,391.7 million, slightly up from RMB 2,371.7 million for the year ending December 31, 2024[4]. - The company's total revenue for the year ended December 31, 2025, was approximately RMB 2,391.7 million, representing an increase of about 0.8% compared to RMB 2,371.7 million for the year ended December 31, 2024[20]. - The company reported a net profit of approximately RMB 11.1 million for the current year, a turnaround from a net loss of approximately RMB 58.3 million for the year ended December 31, 2024, driven by improved gross margins across all business segments[37]. - Adjusted profit for the current year was approximately RMB 38.9 million, compared to an adjusted loss of about RMB 30.5 million for the year ended December 31, 2024[38]. - The company reported a pre-tax profit of RMB 1,670,641,000 for 2025, compared to RMB 1,526,730,000 in 2024, reflecting an increase of 9.4%[88]. - The company's net profit attributable to shareholders for 2025 is RMB 13,544,000, compared to a loss of RMB 56,952,000 in 2024, indicating a significant turnaround in performance[90]. Revenue Breakdown - Revenue from equipment subscription services was approximately RMB 389.3 million, a 2.6% increase from RMB 379.5 million in the previous year[13]. - Revenue from IT technology subscription services rose by 7.0% to approximately RMB 167.4 million from RMB 156.5 million in the previous year[14]. - Revenue from equipment recovery business was RMB 1,834,900 thousand, while equipment subscription services generated RMB 556,762 thousand in 2025[78]. - Revenue from equipment recovery for 2025 is RMB 1,834,900,000, slightly down from RMB 1,835,688,000 in 2024, representing a decrease of 0.04%[81]. - Total customer contract revenue for 2025 is RMB 2,055,960,000, an increase of 0.63% from RMB 2,042,989,000 in 2024[82]. - Revenue from IT technology subscription services increased to RMB 167,449,000 in 2025 from RMB 156,549,000 in 2024, marking a growth of 6.06%[81]. - Short-term equipment subscription revenue for 2025 is RMB 53,611,000, compared to RMB 50,752,000 in 2024, indicating a growth of 5.43%[81]. - Rental income from long-term subscription equipment for 2025 is RMB 335,702,000, up from RMB 328,730,000 in 2024, an increase of 2.95%[86]. Cost and Expenses - The gross profit for the year was approximately RMB 248.1 million, a 26.3% increase from RMB 196.4 million in the previous year, with the gross margin rising from 8.3% to 10.4%[27]. - Sales costs decreased to approximately RMB 2,143.5 million, accounting for about 89.6% of total revenue, down from 91.7% in the previous year[26]. - Distribution and selling expenses decreased by approximately 7.2% to RMB 132.8 million, with the percentage of revenue falling from about 6.0% to 5.6%[32]. - Administrative expenses were reduced by approximately 8.8% to RMB 85.5 million, with the percentage of revenue decreasing from about 4.0% to 3.6%[33]. - R&D expenses decreased by approximately 12.7% from RMB 25.1 million for the year ended December 31, 2024, to about RMB 21.9 million for the current year, representing about 0.9% of revenue compared to 1.1% previously[34]. - The company’s financing costs for 2025 amounted to RMB 49,026,000, an increase from RMB 47,562,000 in 2024[87]. Assets and Liabilities - Current assets increased by approximately 14.6% from RMB 893.4 million as of December 31, 2024, to about RMB 1,023.8 million as of December 31, 2025, with a current ratio of approximately 1.3 times[45]. - Inventory rose from approximately RMB 102.8 million as of December 31, 2024, to about RMB 121.9 million as of December 31, 2025, due to increased demand for obsolete IT equipment[47]. - Trade and lease receivables decreased from approximately RMB 255.6 million as of December 31, 2024, to about RMB 139.9 million as of December 31, 2025, reflecting ongoing efforts to recover receivables[48]. - Trade payables increased by approximately RMB 17.1 million from RMB 107.4 million as of December 31, 2024, to about RMB 124.5 million as of December 31, 2025, due to longer credit terms obtained from suppliers[50]. - As of December 31, 2025, other payables and accrued expenses amounted to approximately RMB 827 million, an increase of RMB 150 million from RMB 677 million as of December 31, 2024, primarily due to accrued employee costs rising from RMB 318 million to RMB 396 million[51]. - Bank balances and cash increased to approximately RMB 4,817 million as of December 31, 2025, compared to RMB 2,959 million as of December 31, 2024, due to ongoing efforts in recovering trade and lease receivables[53]. - The company's total bank borrowings were approximately RMB 5,073 million as of December 31, 2025, down from RMB 5,312 million as of December 31, 2024, with other borrowings increasing to RMB 3,279 million from RMB 2,780 million[54]. - The debt-to-equity ratio was 112.0% as of December 31, 2025, slightly down from 113.0% as of December 31, 2024[55]. - Total liabilities increased to RMB 1,076,247 thousand in 2025 from RMB 1,006,128 thousand in 2024, with current liabilities slightly up to RMB 771,290 thousand[73]. - The company’s net assets increased to RMB 745,405 thousand in 2025 from RMB 716,202 thousand in 2024[73]. Corporate Governance and Other Information - The company has adopted a corporate governance code and aims to maintain high standards of corporate governance[62]. - The audit committee reviewed the consolidated financial statements and confirmed they were prepared in accordance with applicable accounting standards[67]. - The company did not recommend a final dividend for the year, consistent with the previous year[68]. - The company did not declare or pay any dividends for the years ended December 31, 2025, and 2024[89]. - The company had no significant investments, acquisitions, or disposals during the year[56]. - There are no major contingent liabilities as of December 31, 2025[58].

Financial Performance - The group's total revenue for the year ended December 31, 2025, was HKD 203,446,000, representing an increase of 6.5% from HKD 191,885,000 in 2024[3] - The group's net profit attributable to equity holders for the year was HKD 80,430,000, a significant increase from HKD 10,335,000 in 2024, marking a growth of 678%[4] - The group's earnings before tax for 2025 was HKD 83,422,000, compared to HKD 31,015,000 in 2024, reflecting an increase of 168%[4] - The total comprehensive income for the year was HKD 124,598,000, compared to a loss of HKD 4,337,000 in 2024[5] - The reported revenue for the year ending December 31, 2025, is HKD 203,025,000, an increase from HKD 191,865,000 in 2024, representing a growth of approximately 5.9%[25] - The pre-tax profit for the same period is HKD 91,614,000, significantly higher than HKD 43,567,000 in 2024, indicating an increase of about 109.0%[26] - The group’s net profit after tax was HKD 80.43 million, a significant increase of 678% compared to HKD 10.34 million in the previous year[61] Revenue Breakdown - Revenue from asset management services decreased to HKD 11,579,000 in 2025 from HKD 13,888,000 in 2024, a decline of about 16.6%[13] - The total income from client contracts was HKD 93,787,000 in 2025, down from HKD 126,980,000 in 2024, reflecting a decrease of about 26.1%[14] - The asset management segment's revenue decreased by 33% to HKD 28.1 million, primarily due to the absence of consulting income recognized in the previous year[64] - The fixed income investment segment achieved a revenue of HKD 92.56 million, a 139% increase from HKD 38.74 million last year, with a profit of HKD 68.02 million compared to HKD 16.57 million in 2024[68] Assets and Liabilities - The group's total assets as of December 31, 2025, amounted to HKD 2,126,753,000, an increase from HKD 1,381,257,000 in 2024[6] - The total assets reported for 2025 amount to HKD 2,583,924,000, compared to HKD 1,864,194,000 in 2024, marking an increase of about 38.5%[26] - The total liabilities for 2025 are HKD 1,523,530,000, up from HKD 928,398,000 in 2024, which is an increase of approximately 64.1%[26] - The group's current liabilities increased to HKD 1,497,271,000 in 2025 from HKD 928,398,000 in 2024[6] - The net current asset value for the group was HKD 629,482,000, up from HKD 452,859,000 in 2024[6] Costs and Expenses - The group reported a significant reduction in employee costs to HKD 53,346,000 from HKD 55,197,000 in 2024[3] - Total operating expenses for 2025 increased to HKD 62,408,000 from HKD 50,796,000 in 2024, representing a 22% increase[30] - Interest expenses on borrowings rose to HKD 38,182,000 in 2025, up from HKD 29,698,000 in 2024, marking a 29% increase[31] - The company’s financing costs increased to HKD 39,502,000 in 2025 from HKD 30,450,000 in 2024, which is an increase of about 29.8%[26] Investments and Income - Investment income surged to HKD 92,563,000 in 2025, compared to HKD 38,024,000 in 2024, marking an increase of approximately 143.5%[13] - The company’s investment income from external clients for 2025 is HKD 38,736,000, a decrease from HKD 48,116,000 in 2024, representing a decline of about 19.5%[22] - The company’s interest income from bank deposits for 2025 is HKD 11,491,000, compared to HKD 16,725,000 in 2024, indicating a decrease of approximately 31.5%[26] Shareholder Information - The company proposed a final dividend of HKD 0.05 per share for the fiscal year ending December 31, 2025, compared to no dividend in 2024[34] - The board proposes a final dividend of HKD 0.05 per share for the year ended December 31, 2025, subject to shareholder approval at the upcoming annual general meeting[80] - The record date for shareholders to attend and vote at the 2026 Annual General Meeting is set for May 11, 2026[82] - The company will suspend share transfer registration from May 21, 2026, to May 26, 2026, to determine eligibility for the proposed final dividend for 2025[82] Corporate Governance - The board is committed to maintaining high standards of corporate governance and has established policies in line with the corporate governance code[86] - The board held only two regular meetings during the fiscal year 2025, which is below the recommended frequency of four meetings per year[87] - The company has adopted standard codes for director transactions involving the company's securities, confirming compliance for the fiscal year 2025[88] - The audit committee reviewed the internal controls and financial reporting matters for the year ending December 31, 2025[89] Market and Economic Outlook - The U.S. GDP growth accelerated to 4.3% in Q3 2025, up from 3.8% in Q2 2025, marking the best performance in nearly two years[54] - The U.S. Federal Reserve cut interest rates by 25 basis points in December 2025, bringing the target range to 3.50% to 3.75%[55] - The forecast for Hong Kong's GDP growth in 2025 has been revised upwards to 3.2%, from an earlier estimate of 2% to 3%, driven by strong export performance and local demand[71] - The outlook for 2026 indicates potential economic challenges, with expected GDP growth of 2.5%, reflecting a slowdown compared to 2025[71] - Geopolitical risks and U.S.-China tensions are identified as potential downward risks for the Hong Kong stock market in 2026, alongside adjustments in AI valuations[72] Employee Information - The group emphasizes talent development and has established performance indicators for employee evaluations[79] - The group has 78 full-time employees as of December 31, 2025, with an equal gender distribution of 39 male and 39 female employees[78] Regulatory Compliance - The company operates under the regulations of the Hong Kong Stock Exchange and adheres to the Standard Code for securities trading[96] - The financial reporting and compliance are governed by the Securities and Futures Commission of Hong Kong[96] - The company plans to amend existing articles and adopt new articles to comply with Bermuda laws and listing rules, pending shareholder approval at the 2026 AGM[91]

Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 89.44 billion, an increase of RMB 2.47 billion or 2.84% compared to RMB 86.97 billion in the previous year[3]. - The net profit attributable to the parent company for the fiscal year was RMB 1.77 billion, a decrease of RMB 4.22 billion or 19.30% from RMB 2.19 billion in the previous year[3]. - The total operating costs for the fiscal year were RMB 84.62 billion, up from RMB 81.42 billion in the previous year, reflecting an increase of RMB 3.20 billion[4]. - The total comprehensive income attributable to the parent company was RMB 1.80 billion, compared to RMB 2.41 billion in the previous year, indicating a decrease of RMB 610 million[5]. - The basic and diluted earnings per share for the fiscal year were both RMB 0.221, down from RMB 0.274 in the previous year[5]. - The company's operating profit for 2025 was RMB 5.367 billion, a decrease of RMB 0.675 billion or 11.17% from RMB 6.042 billion, mainly due to changes in product structure leading to a decline in gross margin[53]. Assets and Liabilities - The company's total assets as of December 31, 2025, amounted to RMB 161.69 billion, compared to RMB 158.76 billion as of December 31, 2024[6]. - Total assets increased to RMB 206.60 billion as of December 31, 2025, up from RMB 202.04 billion in 2024, representing a growth of 2.78%[10]. - Total liabilities rose to RMB 107.22 billion in 2025, compared to RMB 105.40 billion in 2024, marking an increase of 1.73%[10]. - Non-current assets totaled RMB 44.91 billion as of December 31, 2025, up from RMB 43.28 billion in 2024, indicating a growth of 3.76%[10]. - The company's retained earnings reached RMB 11.38 billion in 2025, up from RMB 10.33 billion in 2024, an increase of 10.19%[10]. Cash Flow - The net cash flow from operating activities for 2025 was a cash outflow of RMB 8.121 billion, a decrease of RMB 10.291 billion compared to the previous year[69]. - The net cash flow from investment activities for 2025 was a cash outflow of RMB 2.603 billion, which is a 51.50% improvement compared to the previous year's outflow of RMB 5.367 billion[69]. - The net cash flow from financing activities for 2025 was RMB 442 million, a significant decrease of 91.72% from RMB 5.336 billion in the previous year[69]. Dividends - The company proposed a final dividend of RMB 530.19 million, translating to RMB 0.0665 per share, down from RMB 0.081 per share in the previous year[3]. - The proposed final dividend per share is RMB 0.0665, down from RMB 0.081 in the previous year, with total dividends amounting to RMB 530,194,807 compared to RMB 645,801,194 previously[31]. Research and Development - The company's research and development expenses for the fiscal year were RMB 6.16 billion, down from RMB 6.66 billion in the previous year[4]. - Research and development expenses totaled RMB 6.155 billion, a decrease of RMB 0.506 billion or 7.60% from RMB 6.661 billion, accounting for 6.88% of total revenue, down 0.78 percentage points year-on-year[51]. Accounts Receivable and Payable - The accounts receivable at year-end amounted to RMB 57.905 billion, up from RMB 50.721 billion at the beginning of the year, reflecting an increase of RMB 7.184 billion or 14.18%[38]. - The total accounts payable at year-end was RMB 51.095 billion, an increase of RMB 5.193 billion or 11.31% from RMB 45.902 billion at the beginning of the year[44]. Governance and Management - The Audit and Risk Management Committee consists of four members, with Mr. Mao Fugeng as the chairman, overseeing financial operations and risk management[92]. - The company has adopted the Corporate Governance Code and believes it has complied with the relevant provisions[102]. - The company is controlled by China Aviation Industry Group, holding a 59.63% stake[107]. Strategic Focus - The company is focusing on enhancing core competitiveness in the helicopter business and expanding into low-altitude economic applications, with ongoing development of new helicopter models and successful test flights[63][64]. - The group aims to enhance core competitiveness and strengthen strategic layout in emerging industries, focusing on low-altitude economy development opportunities[67]. - The company plans to enhance its market presence through strategic acquisitions and partnerships in the aviation sector[108].

Financial Performance - Revenue for the six months ended December 31, 2025, was RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million in the same period of 2024[14]. - Gross profit decreased by 32.7% to RMB 47.4 million from RMB 70.4 million year-on-year[14]. - The operating loss improved to RMB 3.4 million from RMB 7.9 million, a reduction of RMB 4.5 million[14]. - Adjusted EBITDA increased to RMB 3.3 million, up RMB 4.4 million from a loss of RMB 1.1 million in the previous year[14]. - Basic loss per share improved to RMB (6.21) cents from RMB (10.00) cents, a decrease of RMB 3.79 cents[14]. - Loss attributable to owners of the Company for the Period was RMB 6.1 million, an improvement from a loss of RMB 8.0 million in the same period of 2024[60]. - The Group recorded overall revenue of RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million for the corresponding period in 2024[60]. - Gross profit for the same period was RMB 47,448,000, down 32.5% from RMB 70,363,000 in 2024[158]. - Operating loss narrowed to RMB 3,406,000 from RMB 7,933,000 year-over-year[158]. - The company reported a comprehensive loss of RMB 6,058,000 for the period, which includes a loss of RMB 8,012,000 for the period and total other comprehensive income of RMB 2,249,000[162]. Liquidity and Financial Position - The current ratio increased to 1.5 from 1.3, indicating improved liquidity[14]. - Cash and cash equivalents significantly increased to RMB 63,096,000 from RMB 13,403,000, indicating improved liquidity[155]. - Net cash flows from operating activities amounted to RMB 21.1 million during the period, compared to RMB 8.7 million for the six months ended December 31, 2024[84]. - The Group had total borrowings from banks of RMB 25.0 million at an interest rate of 3.5% per annum, with a gearing ratio of N/A as of December 31, 2025, compared to 3.7% as of June 30, 2025[92]. - The total financial liabilities as of December 31, 2025, are RMB 25,856,000, slightly down from RMB 26,464,000 as of June 30, 2025[188]. - The financial liabilities due within less than 1 year amount to RMB 5,796,000, a significant increase from RMB 887,000 as of June 30, 2025[188]. Operational Efficiency - Trade receivables turnover days decreased to 29.2 days from 33.4 days, reflecting better collection efficiency[14]. - Inventory turnover days improved to 54.3 days from 57.5 days, indicating more efficient inventory management[14]. - Trade payables turnover days decreased significantly to 50.2 days from 80.6 days, suggesting improved payment terms[14]. - Selling and marketing expenses were RMB 32.8 million, a decrease of 45.3% from RMB 60.0 million in the previous year, accounting for 12.3% of the Group's revenue[74]. - Administrative expenses were RMB 18.1 million, a slight decrease of 2.7% from RMB 18.6 million in the previous year, accounting for 6.8% of the Group's revenue[76]. Market Trends and Strategic Focus - The healthcare industry in China is experiencing structural growth driven by population aging and high prevalence of chronic diseases, with a rising demand for chronic disease management and health foods[21][28]. - The Group is focusing on expanding its traditional retail chain stores and distribution network while implementing "Direct to Patient (DTP) pharmacies" to adapt to industry trends[30][33]. - The introduction of new service models, such as telephone ordering and home delivery, has enhanced overall service coverage and user experience[32][33]. - The Group is actively promoting digital transformation to improve its online operational infrastructure and build a more efficient network service system[34]. - The "new silver-haired generation" (aged 50-70) is increasingly emphasizing preventive health management, influencing market trends towards nutritional supplements and health monitoring devices[27][29]. - The Group is committed to enhancing employee training to optimize service capabilities within its retail chain system[31]. - The healthcare market potential is expected to expand further, driven by policy guidance, technological advancement, and rising health consumption awareness[28]. Corporate Governance and Compliance - The Company aims to expand its presence outside Mainland China to maximize shareholder returns and will evaluate viable options for this expansion[103]. - The Group will enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[112]. - The company has complied with the Corporate Governance Code, with some deviations noted regarding the roles of chairman and CEO[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the period[120]. Share Capital and Options - The Company issued 30,440,263 shares, representing approximately 27.54% of the enlarged issued share capital, at a subscription price of HK$0.08 per share[116]. - The subscription agreement was approved by shareholders in an extraordinary general meeting held on July 23, 2025[117]. - The company granted a total of 20,000,000 share options in September 2017 and 30,000,000 share options in March 2019 to eligible participants, all of which were accepted[127]. - The total number of share options outstanding as of December 31, 2025, is 2,247,000, with no options exercised during the period[143]. - The company’s share option scheme expired on November 17, 2023, and there are no other share schemes currently in force[145]. Social Responsibility and Community Engagement - The Group actively participated in public welfare activities and health education initiatives to enhance corporate reputation and fulfill social responsibilities[50][56].

Product Development and Clinical Trials - The core product HTD1801 is a novel molecular entity aimed at addressing cardiovascular, kidney, and metabolic diseases, demonstrating multiple metabolic benefits including improved blood sugar control and reduced inflammation markers [5]. - HTD1801 has shown significant clinical data supporting its efficacy, including a reduction in LDL-C and non-HDL-C levels, and improvement in kidney function indicators [8]. - The company is developing HTD1801 for multiple indications, including Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), and Nonalcoholic Steatohepatitis (NASH) [9]. - Clinical trials for HTD1801 involve over 2,000 participants, indicating a strong commitment to safety and efficacy [8]. - The company aims to expand HTD1801's indications to address unmet clinical needs in CKM-related diseases, which affect nearly 90% of adults in the U.S. and 80% in China [6]. - The company is conducting high-quality multicenter clinical trials across the U.S., China, Canada, and Australia, ensuring a broad market reach [10]. - HTD1801's dual mechanism of action targets chronic inflammation and metabolic imbalance, addressing significant unmet needs in CKM diseases [6]. - HTD1801 has received two Fast Track designations and one Orphan Drug designation from the FDA, and has been supported by China's "13th Five-Year Plan" for major new drug creation [14]. - Three Phase III trials for T2DM in China were completed in 2025, with the NDA for HTD1801 accepted by the NMPA in March 2026 [14]. - In the Phase III trial (SYMPHONY-2), HTD1801 demonstrated a statistically significant reduction in HbA1c of -1.21% compared to -0.68% in the placebo group (p<0.0001), with 33% of patients achieving HbA1c <7% [16]. - HTD1801 showed potential renal protective effects by improving eGFR in patients with mild renal impairment [16]. - In the Phase III trial (SYMPHONY-1), HTD1801 achieved a significant reduction in HbA1c of -1.3%, with 42% of patients reaching HbA1c <7% [17]. - HTD1801 demonstrated a significant reduction in LDL-C and non-HDL-C, indicating its ability to lower both glucose and lipids [17]. - The drug exhibited good safety and tolerability profiles across multiple studies, supporting its potential as a unique oral treatment for T2DM and its complications [17]. - HTD1801 showed dose-dependent improvements in multiple liver and cardiovascular metabolic markers in patients with suspected MASLD [17]. - HTD1801 demonstrated a significant reduction in HbA1c by -1.12% after 24 weeks of treatment, compared to -0.93% in the Dapagliflozin group, achieving statistical significance (P < 0.001) [20]. - In the SYMPHONY studies, HTD1801 maintained long-term efficacy with sustained benefits observed at 52 weeks, showing improvements in multiple cardiometabolic markers [18]. - The safety profile of HTD1801 was favorable, with a serious adverse event rate of 3.8%, lower than the 4.4% in the Dapagliflozin group, and no severe hypoglycemic events reported [20]. - HTD1801 showed significant potential in chronic kidney disease (CKD) treatment, improving eGFR in patients with mild renal impairment (baseline eGFR: 60-89 mL/min/1.73m²) [20]. - Preclinical studies indicated that HTD1801 could reduce serum creatinine and urea nitrogen levels, alleviating renal inflammation and fibrosis [20]. - The HARMONY study demonstrated that HTD1801 outperformed Dapagliflozin in improving key cardiovascular metabolic indicators in T2DM patients [18]. - HTD1801 achieved multiple secondary endpoints, showing superior reductions in LDL-C and non-HDL-C compared to Dapagliflozin [20]. - The SYMPHONY studies confirmed HTD1801's comprehensive benefits beyond glycemic control, including improvements in kidney and metabolic health [18]. - HTD1801 is positioned as an innovative treatment option for complex CKD-related diseases, targeting both metabolic and inflammatory pathways [20]. - HTD1801 demonstrated significant improvement in eGFR in patients with mild renal impairment compared to placebo, with a positive slope during treatment [22]. - In a global multicenter Phase IIb study, 48% of patients in the placebo group achieved a NAS score reduction of ≥2 points without fibrosis worsening, significantly higher than previous studies [22]. - HTD1801 showed greater improvements in liver injury and inflammation markers, blood glucose control, weight loss, and lipid metabolism compared to GLP-1RAs in patients with MASH and T2DM [23]. - In a Phase IIa clinical trial, patients with MASH and T2DM experienced an average weight loss of 3.5 kg, with those having high insulin levels losing an average of 8 kg [26]. - The treatment of HTD1801 showed a twofold increase in patients achieving liver histological improvement compared to the placebo group in patients at risk of progression [22]. - HTD1801's gastrointestinal tolerance improved over time, supporting its potential for long-term use in chronic disease treatment [23]. - The company plans to initiate a Phase II clinical study of HTD1801 combined with GLP-1RA for obesity treatment [26]. - HTD1801 has shown potential in treating various metabolic diseases, including obesity, by improving inflammation and metabolic dysfunction [26]. - The company is evaluating the clinical development strategy for HTD1801 in MASH indications based on comprehensive data and regulatory feedback [23]. - HTD1801 demonstrated a statistically significant reduction in serum alkaline phosphatase levels compared to the placebo group in the Phase II clinical trial for PSC, indicating its efficacy in treating cholestatic liver disease [28]. Financial Performance - The company recorded a loss of approximately RMB 232.1 million for the year ending December 31, 2025, compared to a loss of approximately RMB 381.8 million for the year ending December 31, 2024 [44]. - The company reported a net loss of RMB 232.1 million for the year 2025, compared to a net loss of RMB 381.8 million in 2024, indicating a 39% improvement year-over-year [61]. - Adjusted net loss for 2025 was RMB 205.0 million, improved from RMB 284.9 million in 2024, reflecting a 28% reduction [61]. - Total employee benefits expenses for 2025 amounted to approximately RMB 49.2 million, down from RMB 108.2 million in 2024, primarily due to a decrease in long-term incentive plan expenses [63]. - The company had a total of 51 employees as of December 31, 2025, a decrease from 70 employees as of December 31, 2024, representing a 27% reduction [63]. - The company reported a total revenue of RMB 19,007,000, a decrease of 72% compared to RMB 67,971,000 in 2024 [81]. - The company incurred a pre-tax loss of RMB 231,882,000 for 2025, an improvement of 39% from a loss of 381,519,000 in 2024 [81]. - The net loss attributable to the owners of the company for 2025 was RMB 244,968,000, compared to RMB 381,788,000 in 2024, reflecting a 36% reduction in losses [81]. - The company's basic and diluted loss per share for 2025 was RMB 0.51, improving from RMB 0.84 in 2024 [81]. - Total comprehensive loss for the year was RMB 239,654,000, a decrease of 36% from RMB 375,538,000 in 2024 [82]. - As of December 31, 2025, total assets amounted to RMB 532,188,000, slightly up from RMB 513,371,000 in 2024 [83]. - The company's cash and cash equivalents decreased to RMB 232,388,000 in 2025 from RMB 310,750,000 in 2024, indicating a 25% decline [83]. - Non-current assets decreased significantly to RMB 19,152,000 in 2025 from RMB 46,560,000 in 2024, a reduction of 59% [83]. - The company's total equity decreased to RMB 364,666,000 in 2025 from RMB 424,168,000 in 2024, reflecting a decline of 14% [84]. - Other income decreased from approximately RMB 68.0 million for the year ending December 31, 2024, to about RMB 19.0 million for the year ending December 31, 2025, a reduction of 72.1% [38]. - Net other losses increased from approximately RMB 3.2 million for the year ending December 31, 2024, to about RMB 25.0 million for the year ending December 31, 2025, primarily due to an increase in fair value losses on financial assets of approximately RMB 20.1 million [39]. - Research and development costs decreased by 54.7% from approximately RMB 363.5 million for the year ending December 31, 2024, to about RMB 164.5 million for the year ending December 31, 2025, mainly due to a reduction in third-party contract expenses of approximately RMB 156.2 million [40]. - Administrative expenses decreased from approximately RMB 81.2 million for the year ending December 31, 2024, to about RMB 59.1 million for the year ending December 31, 2025, a reduction of 27.2% [42]. - Financing costs increased from approximately RMB 1.5 million for the year ending December 31, 2024, to about RMB 2.4 million for the year ending December 31, 2025, primarily due to an increase in interest on bank borrowings of approximately RMB 0.9 million [43]. - The company has not engaged in any significant litigation that could adversely affect its financial condition or operating results during the reporting period [69]. - The net proceeds from the IPO amounted to approximately HKD 194.1 million, with a remaining balance of approximately HKD 9.3 million as of the end of the reporting period [70]. - The company raised approximately HKD 123.4 million from the placement of shares, with a net amount of HKD 110.4 million remaining unutilized at the end of the reporting period [74]. - The company did not recommend the distribution of a final dividend for the year ending December 31, 2025 [78]. - The ongoing clinical research for HTD1801 has a budget allocation of HKD 164.2 million, with HKD 104.3 million utilized during the reporting period [71]. - The audit committee has reviewed the financial performance for the year ending December 31, 2025, and found it compliant with relevant accounting standards [76]. - The company believes that the reallocation of funds will not result in any significant adverse impact on its existing business and operations [72]. Corporate Governance and Compliance - The company has complied with all applicable corporate governance codes during the reporting period, except for a deviation regarding the separation of the roles of Chairman and CEO [65][66]. - The company adopted a share incentive plan on January 22, 2020, May 24, 2023, and June 27, 2025, to enhance employee motivation and retention [64]. - The company does not currently have a foreign currency hedging policy but monitors foreign exchange risks and may consider hedging significant foreign currency risks as needed [58]. - The company is currently evaluating the impact of IFRS 18 on its consolidated financial statements, which will affect the presentation and disclosure of comprehensive income [90]. - The company operates primarily in the biopharmaceutical research and development sector, reported as a single reportable segment [91]. - The majority of non-current assets are located in mainland China, leading to no regional segment information being presented [92]. - The board of directors includes both executive and non-executive members, ensuring a diverse governance structure [109].

Financial Performance - The group recorded revenue of approximately HKD 1,785,563,000, a decrease of 2.6% from HKD 1,833,795,000 in the previous year[4] - The net profit for the year was approximately HKD 64,800,000, compared to a net loss of HKD 158,207,000 in the previous year[4] - Operating profit for the year, excluding other income and losses, was approximately HKD 87,501,000, an increase of 23.5% from HKD 70,855,000 in the previous year[4] - The total comprehensive income for the year was HKD 96,101,000, a significant recovery from a loss of HKD 223,576,000 in the previous year[6] - The group reported a basic and diluted earnings per share of HKD 0.21, compared to a loss per share of HKD 3.01 in the previous year[6] - The group proposed a final dividend of HKD 0.18 per share, up from HKD 0.12 per share in the previous year[3] Assets and Liabilities - The group's total assets amounted to approximately HKD 3,398,824,000, slightly up from HKD 3,380,347,000 in the previous year[4] - The debt ratio decreased to 0.36% from 2.71% in the previous year, reflecting improved financial leverage[4] - The group's current assets net value was approximately HKD 1,329,944,000, compared to HKD 1,300,647,000 in 2024, with a current ratio of 3.64, up from 3.19 in 2024[88] - The group has pledged assets valued at approximately HKD 28,340,000 as of December 31, 2025, a decrease from HKD 120,545,000 in 2024[94] Revenue Breakdown - Total revenue for the year was HKD 1,777,879,000, a decrease of 2.5% from HKD 1,823,021,000 in the previous year[18] - Revenue from Hong Kong medical services was HKD 731,898,000, down from HKD 787,053,000, representing a decline of 7.0%[16] - Revenue from mainland China hospital management and medical services increased to HKD 584,884,000, up from HKD 546,615,000, reflecting a growth of 7.0%[16] - The group reported a total segment revenue of HKD 1,785,563,000, with external sales contributing HKD 1,785,563,000 and inter-segment sales of HKD 35,577,000[22] Operational Efficiency and Strategy - The company aims to enhance operational efficiency and optimize patient experience in response to the challenging economic environment[50] - The group continues to optimize its network layout in Hong Kong to enhance operational efficiency and resource effectiveness, including the establishment of multi-clinic centers[57] - The introduction of telemedicine services and a mobile app aims to improve accessibility and efficiency in healthcare delivery, with services available seven days a week[60] - The group is focusing on optimizing service processes through technology, including the introduction of WhatsApp appointment services to enhance customer experience[63] Future Projections and Plans - The group’s total revenue for the fiscal year ending December 31, 2025, is projected to be HKD 1,773,165,000 under the gross basis accounting method[19] - The company plans to enhance operational efficiency and resource allocation to reduce healthcare service costs while improving overall medical experience[82] - A new multi-clinic "Health Comprehensive Medical Center" will be established in North Point, Hong Kong, to provide convenient and efficient one-stop medical services[82] Governance and Compliance - The company has adopted its own corporate governance code in accordance with the principles and provisions of the corporate governance code this year[103] - The roles of the Chairman and CEO are held by the same individual, Mr. Choi Ka-Chan, which deviates from the code but is believed to ensure consistent leadership and operational efficiency[104] - The auditor, Deloitte Touche Tohmatsu, has been reappointed at the annual general meetings held from 2018 to 2025[106] Market and Industry Trends - The healthcare industry in mainland China is undergoing a deep transformation, with a focus on high-quality development and the allocation of quality medical resources[51] - The demand for primary healthcare, specialist treatment, health management, and rehabilitation services is expected to continue growing due to an aging population and increased health awareness[81] Employee and Operational Metrics - The total employee cost for the year was approximately HKD 706,701,000, down from HKD 743,697,000 in 2024, with 1,345 employees as of December 31, 2025[92] - The group has identified four operating and reporting segments: Hong Kong medical services, Hong Kong medical network management, mainland China hospital management and medical services, and others[20]

Company Overview - Everbright Water operates across 13 provinces and regions in China, including major cities like Beijing and Shanghai, and has international operations in countries like Mauritius[11]. - The company is committed to transforming into a technology-driven environmental service provider, focusing on core business areas such as water supply and wastewater treatment[13]. - The company emphasizes sustainable urban development and ecological balance in its operations, aligning with its mission of "Safeguarding Clean Water"[5]. - Everbright Water has developed a full industry chain in the water business, including project investment, planning, design, R&D, engineering, and operations management[11]. - The company is listed on both the Singapore Exchange and the Hong Kong Stock Exchange, with stock codes U9E.SG and 1857.HK respectively[10]. - The board of directors includes key figures such as Mr. Luan Zusheng (Chairman) and Mr. Xiong Jianping (CEO), ensuring strong leadership[14]. Financial Performance - Revenue for FY2025 decreased by 22% to HK$5,355,110, compared to HK$6,851,918 in FY2024[31]. - Gross profit for FY2025 was HK$2,357,921, down 10% from HK$2,617,462 in FY2024[31]. - EBITDA for FY2025 declined by 12% to HK$1,934,630 from HK$2,197,255 in FY2024[31]. - Profit attributable to equity holders of the company fell by 17% to HK$842,475, compared to HK$1,019,609 in FY2024[31]. - Return on shareholders' equity decreased to 6.8% in FY2025 from 8.8% in FY2024, a drop of 2.0 percentage points[31]. - Basic earnings per share for FY2025 were HK$29.45, down 17% from HK$35.64 in FY2024[31]. - Total assets increased by 6% to HK$38,218,241 as of December 31, 2025, compared to HK$35,889,362 in 2024[31]. - Total liabilities also rose by 6% to HK$23,183,850 from HK$21,897,684 in the previous year[31]. - Equity attributable to equity holders of the company grew by 8% to HK$12,835,487 from HK$11,835,120[31]. - Proposed final dividend for FY2025 is HK$4.22 per share, subject to shareholder approval[27]. Market Position and Recognition - In FY2025, the company achieved a significant improvement in its market position, rising from 89th to 49th in the Singapore Governance and Transparency Index[46]. - The company was awarded the "Highest Weighted Return on Equity Over Three Years" and the "Overall Sector Winner" in the Utilities Sector under the Centurion Club, highlighting strong capital returns and operational efficiency[46]. Sustainability and Environmental Initiatives - The company launched a series of environmental protection activities for the eighth consecutive year, fulfilling its corporate social responsibility[39]. - The company established a sustainability committee to oversee ESG matters and signed an investment cooperation agreement for zero-carbon energy projects with the Daxing District People's Government[43]. - The Group's commitment to sustainable operations included deploying clean energy technologies, such as solar power, to reduce carbon footprint[58]. - The Group's projects ensure effluent discharge meets or exceeds the Grade 1A standard under the Discharge Standard of Pollutants for Municipal Wastewater Treatment Plant (GB18918-2002)[170]. - The Group's ongoing efforts in environmental education and public engagement aim to enhance awareness of water resource protection and sustainability[173]. Operational Efficiency and Management - The Group's operational efficiency was driven by refined management and digital transformation, leading to cost optimization[58]. - The Group's initiatives in technology and innovation included advancing water treatment technologies towards low-carbon and intelligent solutions[57]. - The Group's operational management focused on refined management, achieving significant reductions in key operational costs, including single product procurement costs and chemical dosing costs[86]. - The Group enhanced liquidity management by forecasting cash flows and optimizing capital utilization, utilizing financial instruments to accelerate cash inflow[159]. - The Group implemented a project management information system to oversee the entire project management process and conducted regular data analysis to strengthen project management capabilities[160]. Research and Development - The company increased R&D investment to advance water treatment technologies, focusing on low-carbon and intelligent upgrades[54]. - In FY2025, the Group secured 25 new intellectual property rights and published 2 key research papers, enhancing its technological innovation capabilities[88]. - A professional research team has been arranged to enhance research efforts on new business opportunities and business expansion within the water industry[150]. Challenges and Risks - The Group faces significant pressure in managing environmental compliance and production safety due to the large number of construction and operational projects across diverse geographical locations[151]. - The Group's principal risks include regulatory changes in wastewater treatment and PPP models, requiring timely measures to mitigate adverse effects on operations[143]. - The risk level associated with trade receivables remains unchanged due to the significant balance, despite effective control measures[159]. Employee and Governance - The Group employed a total of 1,926 employees, with remuneration based on qualifications, experience, and performance[139]. - The Group has established a comprehensive corporate governance framework with five committees to enhance management and risk control[131]. - The Group implemented a talent-driven strategy, focusing on continuous development and specialized training for employees, enhancing organizational performance[138]. Future Outlook - The Group's strategic focus for FY2026 includes optimizing its domestic and international business footprint and exploring new growth opportunities aligned with green transition[62]. - The Group is actively pursuing opportunities for mergers and acquisitions in key regions to expand its business scale and enhance core competitiveness[151].